<DOC>
	<DOCNO>NCT00556894</DOCNO>
	<brief_summary>This trial test hypothesis addition CF101 , novel anti-inflammatory agent , improve clinical condition patient rheumatoid arthritis still active joint inflammation despite take methotrexate least 6 month .</brief_summary>
	<brief_title>Oral CF101 Tablets Methotrexate Treatment Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , parallel-group , placebo-controlled , dose-finding study patient active RA despite receive methotrexate least 6 month ( unchanged dos &gt; =2 month ) randomize addition either CF101 0.1 mg , CF101 1 mg , placebo give orally q12h 12 week . Screening examination occur within 1 month prior dose . Washout disease-modifying antirheumatic drug ( DMARDs ) ( exception hydroxychloroquine ) , include biological agent , occur prior dosing ; washout necessary , patient must re-qualify inclusion follow washout . Doses nonsteroidal anti-inflammatory drug ( NSAIDS ) corticosteroid must stable &gt; =1 month prior dose remain protocol participation . Disease activity assess use swollen tender joint count , physician patient global assessment ( visual analog scale , VAS ) , patient report pain ( VAS ) , Health Assessment Questionnaire ( HAQ ) Disability Index ( DI ) , Westergren erythrocyte sedimentation rate ( ESR , Screening , Weeks 0 and12 ) , C-reactive protein ( CRP ) level . Assessments take place Screening , Baseline ( Week 0 ) , Weeks 2 , 4 , 8 , 12 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Males female age 1875 year Meet criterion American College Rheumatology RA ( Arnett FC et al . Arthritis Rheum 1988 ; 31:315324 ; refer Appendix 1. diagnostic criterion Rheumatoid Arthritis ) Not bed wheelchairbound Active RA , indicate presence ( ) &gt; =6 swollen joint ( 28 joint count ) ; AND ( b ) &gt; =6 tender joint ( 28 joint count ) ; AND either : ( c ) Westergren ESR &gt; =28 mm/hour ; OR ( ) CRP level upper limit normal central reference laboratory Treatment weekly oral parenteral methotrexate &gt; =6 month prior baseline Methotrexate route administration unchanged &gt; =2 month prior baseline Dose methotrexate stable 1525 mg/week &gt; =2 month , expect remain stable throughout study ; stable dose methotrexate may alternatively 1012.5 mg/week document toxicity preclude high dose If take hydroxychloroquine chloroquine , administration duration &gt; =3 month dose stable &gt; =2 month prior baseline If take nonsteroidal antiinflammatory agent ( NSAID ) , dose stable least 1 month prior baseline , remain unchanged protocol participation If take oral corticosteroid , dose &lt; 10 mg/day prednisone equivalent , stable least 1 month prior stabilization period , remain stable stabilization entire treatment followup period Negative screening serum pregnancy test female patient childbearing potential Females childbearing potential must utilize , throughout course trial , 2 method contraception deem adequate Investigator ( example , oral contraceptive pill plus barrier method ) Receipt follow least 1 month stabilization period prior dosing : sulfasalazine , oral injectable gold , azathioprine , minocycline , penicillamine , anakinra Receipt etanercept least 6 week period prior dose Receipt cyclosporine , infliximab adalimumab least 2 month period prior dose Receipt leflunomide least 2 month period prior screening , unless patient undergone cholestyramine washout least 1 month prior dose Receipt cyclophosphamide least 6 month period prior dose Receipt rituximab previous time Participation previous trial CF101 trial Use oral corticosteroid &gt; 10 mg prednisone , equivalent , per day Change NSAID dose level 1 month prior dose Change oral corticosteroid dose level 1 month prior , , stabilization period vChange hydroxychloroquine chloroquine dose level 2 month prior , , stabilization period Receipt parenteral intraarticular corticosteroid 1 month prior , , stabilization period Significant cardiac arrhythmia conduction block , congestive heart failure , evidence clinically significant heart disease ; clinically significant finding screen electrocardiogram ( ECG ) Hemoglobin level &lt; 9.0 gm/dL screen visit Platelet count &lt; 125,000/mm3 screen visit White blood cell count &lt; 3000/mm3 screen visit Serum creatinine level outside central laboratory 's normal limit screen visit Liver aminotransferase ( ALT and/or AST ) level great 1.25 time central laboratory 's upper limit normal screen visit Significant acute chronic medical psychiatric illness , judgment Investigator , could compromise patient safety , limit patient 's ability complete study , and/or compromise objective study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>